Background: The surge in obesity globally has paralleled an alarming rise in type 2 diabetes mellitus (T2DM), prompting a search for effective treatment modalities. Bariatric surgery, evolving as a viable intervention for obesity-associated T2DM, encompasses various procedures like the Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S) and the Mini-Gastric Bypass (MGB). This study aimed to compare the efficacy of SADI-S versus MGB in managing T2DM in obese patients. Methods: This study was conducted at Banha University Hospitals between September 2021 and September 2022. 50 obese patients with T2DM were enrolled and split equally into SADI-S and MGB groups. Preoperative assessments included comprehensive clinical, laboratory, and radiological evaluations, delineated inclusion and exclusion criteria. Patients underwent meticulous preoperative preparation and received detailed postoperative care, including staged diet regimens and follow-up assessments. Results: There was statistically significant difference between groups according to treatment, in Triglycerides and cholesterol after 3, 6, and 12 months. Conclusion:Surgical treatment of T2DM is gaining increasing attention due to the significant influence that weight loss procedures have on glucose metabolism. Carefully selected patients with metabolic syndrome may undergo metabolic surgery without risk. A therapeutic focus is necessary for individuals at high risk due to the heightened susceptibility to type 2 diabetes and cardiovascular disease. According to the findings of our research, SADIS and MGB exhibit comparable efficacy in managing hypertension, diabetes mellitus, and hyperlipidemia.